The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Pretoria, South Africa and Canberra, Australia, 4 October 2024 - The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators.
The MoU builds on the existing relationship between the health products regulators to improve capabilities in the assessment of medical products and therapeutic goods and their monitoring for continued efficacy, safety and quality once they are registered.
Areas of cooperation
SAHPRA and TGA will engage in data sharing aimed at improving the regulatory functions executed by both regulators. This will particularly focus on the assessment and approval of medical products and therapeutic goods, their monitoring for continued efficacy, and the surveillance for safety and adverse reaction (event) concerns.
According to SAHPRA’s Chief Executive Officer, Dr Boitumelo Semete-Makokotlela, the agreement with the TGA expands the geographical reach for both regulators’ pharmacovigilance programmes and augments their internal expertise.
“This partnership enables us to rely on each other’s strengths and regulatory outputs in the evaluation of health products both before they are registered and once they are approved for public use. This would improve therapeutic outcomes for the populations we exist for and increase the robustness of our post-registration surveillance for efficacy, safety and quality,” says Dr Semete-Makokotlela.
Deputy Secretary at the Australian Government Department of Health and Aged Care and head of the TGA, Professor Anthony Lawler, said: “TGA is very pleased to have strengthened our collaborative relationship with SAHPRA with the signing of this international agreement. We look forward to working alongside our regulatory counterparts in South Africa to share important regulatory information to ensure the continued safety, quality and efficacy of therapeutic products approved for market.”
About SAHPRA
SAHPRA is tasked with regulating (monitoring, evaluating, investigating, inspecting and registering) all health products in South Africa. This includes clinical trials, complementary medicines, medical devices and in-vitro diagnostics (IVDs). Furthermore, SAHPRA has the added responsibility of overseeing radiation control. SAHPRA’s mandate is outlined in the Medicines and Related Substances Act, 101 of 1965 (as amended), as well as the Hazardous Substances Act, 15 of 1973. SAHPRA has three pillars to ensure that medicines, medical devices and IVDs meet the requisite standards to protect the health and well-being of all who reside in South Africa: safety, efficacy and quality. It is these three pillars that define the ethos of SAHPRA.
Notes to Editors
SAHPRA will post this media release on its website. Navigate to the News section on the website.
A podcast will be recorded and posted on the home page. Scroll down the home page to “SAHPRA TV and Podcasts”. Podcasts appear on the right-hand side.
Should you wish to request an interview, please send your request to media@sahpra.org.za and Madimetja.Mashishi@sahpra.org.za.
Updates on vaccine registration can be accessed here: Vaccines - News and updates (sahpra.org.za - external site).
Contact for members of the media:
- Email: news@health.gov.au
- Phone: 02 6289 7400.
